Share on LinkedInShare on LinkedIn

ARTICLE · 20 MARCH 2019

Venturing Into EIS And VCT Due Diligence

The industry should, consequentially, continue to flourish.

United KingdomTax

In a  previous article, I outlined the first half of a presentation which I gave in Liverpool, focusing on investment into businesses operating in and around the North-West. More specifically, it addressed the recent review of Inheritance Tax ("IHT") undertaken by the Office for Tax Simplification ("OTS"), and the potential implications, if any, which this could have on qualifying trades, as well as a brief examination into the impact which the AIM sell-off through Q4 2018 may have had on sentiment around AIM IHT products.

In this article, I will address the second topic covered in the presentation: an examination into the effects which the Patient Capital Review ("PCR") has had on the EIS and VCT market, and more pertinently the implications which this has had on the due diligence process in this space.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from